Generic Drugs Market

Generic Drugs Market - Size, Share, Growth,
Outlook, and Opportunity Analysis, 2018-2026
Generic drugs refers to medication that have the same active ingredient as that of a branded drugs.
These drugs also yield the same therapeutic effect and are prescribed in the same dosing, with the
same quality, and same the way of consumption and usage. However, the inactive ingredients of
generic drugs can differ as compared to their branded counter parts. These drugs are mainly
marketed after a patent expiry of a branded drug and are significantly lower in costs as compared to
the patented branded drugs. Generic drugs are of equivalent quality as compared to the branded
drugs and are manufactured under the same safety and manufacturing procedures. Various
manufacturers submit an abbreviated new drug application (ANDA) to the FDA after the completion of
period of patent exclusivity.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1132
Patent expiry of branded drugs is a factor expected to boost growth of the global generic
drugs market
Manufacturers of generic drugs are focusing on development and introduction of various
innovative medication and formulation such as biosimilars. According to IMS Health data, generic
drugs accounted for over 80% of the prescriptions dispensed in the U.S. in 2013. The number of
patents expiring in the near future serves to be a major driver for growth of generic drugs
market.
Asia Pacific to gain significant traction in the global generic drugs market owing to
increasing number of local players
On the basis of region, the global generic drugs market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America held a dominant position in
the global generic drugs market in 2016. This is attributed to favorable regulatory policies that
are revised and amended to encourage generic drugs business in the region. For instance,
Generic Drug User Fee Amendment (GDFUA) was reauthorized in 2017 after its initiation in 2012
by FDA for increasing consumer access to high quality, safe, and affordable drugs. On the other
hand, Asia Pacific is expected to show a significant traction in the market over the forecast
period. This is attributed to lower manufacturing costs and high skilled workforce in the Asian
countries. According to India Brand Equity Foundation, India has the second largest number of
U.S. FDA manufacturing plants outside the U.S. that are involved in generic drugs manufacturing.
Additionally, the cost of manufacturing is 33% lower in India than that in the U.S., increasing
accessibility to generics in these countries.
Report includes chapters which deeply display the following deliverable about industry :
• Generic Drugs Market Research Objective and Assumption
• Generic Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity
Map (COM)
• Generic Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory
Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain
Analysis, Porter’s Analysis, and PEST Analysis
• Global Generic Drugs Market, By Regions
• Generic Drugs Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Generic Drugs Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Generic Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers
of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Generic Drugs Market Forecast including Production, Consumption, Import and Export Forecast by
Type, Applications and Region.
• Research Findings and Conclusion
Key players operating in the global generic drugs market are Teva Pharmaceutical
Industries, Mylan N.V., Novartis International AG, Pfizer, Inc., Allergan Plc, Sun
Pharmaceuticals, Fresenius Kabi, Sanofi, Endo International, Lupin Ltd., Abbott
Healthcare, AstraZeneca Plc, and Novo Nordisk.
Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-toanalyst/1132
Market Taxonomy
The global generic drugs market is segmented on the basis of drug type, therapeutic application,
route of administration, and region.
On the basis of Drug Type, the global generic drugs market is segmented into:
•
•
•
•
•
•
•
•
•
Monoclonal Antibodies
Cytokines
Vaccines
Insulin
Peptide Hormones
Immunoglobulin
Peptide Antibiotics
Blood Factors
Others
On the basis of Therapeutic Application, the global generic drugs market is
segmented into:
•
•
•
•
•
•
Oncology
Cardiovascular Diseases
Neurology
Infectious Diseases
Musculoskeletal Diseases
Others
Based on Route of Administration, the global generic drugs market is segmented into:
•
•
•
•
•
Oral
Topical
Injectable
Intra-venous
Others
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Download Report